CompletedPhase 2NCT00007345
Depsipeptide to Treat Patients With Cutaneous T-Cell Lymphoma and Peripheral T-Cell Lymphoma
Studying Aggressive primary cutaneous T-cell lymphoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- National Cancer Institute (NCI)
- Principal Investigator
- James Gulley, M.D., Pharm.DNational Cancer Institute (NCI)
- Intervention
- Romidepsin(drug)
- Enrollment
- 131 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2001 – 2015
Study locations (13)
- Mayo Clinic Scottsdale, Scottsdale, Arizona, United States
- University of Arkansas, Little Rock, Arkansas, United States
- City of Hope National Cancer Center, Duarte, California, United States
- Mercy General Hospital, Sacramento, California, United States
- Georgetown University, Washington D.C., District of Columbia, United States
- Northwestern University, Chicago, Illinois, United States
- National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
- North Shore University Hospital, Manhasset, New York, United States
- University of Pittsburgh, Pittsburgh, Pennsylvania, United States
- West Virginia University, Morgantown, West Virginia, United States
- Royal Adelaide Hospital, Adelaide, Australia
- Peter MacCallum Cancer Centre, Melbourne, Australia
- Sir Charles Gairdner Hospital, Perth, Australia
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT00007345 on ClinicalTrials.govOther trials for Aggressive primary cutaneous T-cell lymphoma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1NCT05544968Anti-CD30 biAb-AATC in Patients With Relapsed/Refractory CD30 Positive Hematopoietic MalignanciesMedical College of Wisconsin
- RECRUITINGPHASE1NCT07055477A Phase I Trial Anti-CC Chemokine Receptor 4 Chimeric Antigen Receptor T Cells (CCR4 CAR T Cells) for CCR4 Expressing T-cell Malignancies Including Peripheral T-cell Non-Hodgkin Lymphoma (PTCL) and Cutaneous T-cell Non-Hodgkin Lymphoma (CTCL)National Cancer Institute (NCI)
- RECRUITINGPHASE1NCT07047885Ropeginterferon in Patients w/Cutaneous T-Cell Lymphoma (CTCL)H. Lee Moffitt Cancer Center and Research Institute
- RECRUITINGNANCT06860880Combating Cancer-Related Fatigue: A Personalized Supportive Care ProgramUNC Lineberger Comprehensive Cancer Center
- RECRUITINGPHASE1, PHASE2NCT07022964CD5 CAR T-Cell Therapy for r/r T-cell LymphomasBeijing GoBroad Hospital
- RECRUITINGNCT07132567Assessment of Safety and Efficacy of Poteligeo Inj. 20 mg (Mogamulizumab) Through Use-result SurveillanceKyowa Kirin Co., Ltd.
- RECRUITINGPHASE1, PHASE2NCT06925464CD7 CAR T-Cell Therapy for r/r T-cell LymphomasBeijing GoBroad Hospital
- RECRUITINGPHASE1NCT06914037A Clinical Study of CHT101 in CD70-Positive Relapsed or Refractory Hematological MalignanciesTianjin Medical University Cancer Institute and Hospital
See all trials for Aggressive primary cutaneous T-cell lymphoma →